Kosta Y. Mumcuoglu

Важность для гирудотерапии

Kosta Mumcuoglu solved the single most important practical problem facing modern medical leech therapy: Aeromonas hydrophila infection. When the FDA cleared Hirudo verbana as a Class II medical device in June 2004 (K040187), the principal regulatory concern was the documented 7-20% rate of Aeromonas hydrophila infections at leech application sites — infections that, while rarely fatal, could compromise the very flap salvage that leeches were applied to achieve. Mumcuoglu's Hadassah group had been working on this problem since the late 1990s, and his 2003 and 2010 papers established what became the global standard prophylaxis protocol: ciprofloxacin 500 mg orally twice daily starting 24 hours before leech application and continuing for 48 hours after the last leech is removed. His subsequent characterization of the leech gut microbiome was equally important scientifically. Mumcuoglu's 2011 Applied and Environmental Microbiology paper used 16S rRNA pyrosequencing — then a state-of-the-art technique — to show that the medicinal leech's gut contained only two dominant symbionts (Aeromonas veronii and the novel Mucinivorans hirudinis), one of which (A. veronii, related to A. hydrophila) is the source of leech-therapy infections. This finding immediately suggested the prophylactic strategy that Herlin and colleagues later refined into the dual-agent ciprofloxacin + trimethoprim-sulfamethoxazole regimen in 2017. Mumcuoglu's establishment of the Hadassah Medical Leech Farm (1995-2019) was the third pillar of his contribution: it gave the Eastern Mediterranean region a non-CITES-dependent supply of medical-grade leeches and trained a generation of Israeli, Palestinian, and Jordanian clinicians in evidence-based application protocols. His 2018 Springer textbook (co-authored with multiple international leaders) remains the only comprehensive English-language reference for clinicians implementing leech therapy programs. ASH considers him the single most important contemporary figure in making leech therapy infrastructurally feasible at scale.